This article was originally published in Start Up
NanoBio is developing nanoemulsions, which might be able to combat viruses, fungi, and spores that aren't affected by other types of disinfectants.
You may also be interested in...
The founder of Eyeon Therapeutics thinks that his firm will take giant steps forward in the next six months towards commercializing an over-the-counter nanotechnology-based eye drop for treating dry eye.
FDA is building a knowledge base in nanotechnology and testing its current regulatory procedures. But adapting to the new field could stress the agency's already tight resources and may damage its fragile credibility with the public.
In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.